Scientists hunt for clues to stop lifelong hepatitis d drugs
NCT ID NCT06603311
Summary
This study aims to find biological markers in the blood or liver that can tell doctors when it might be safe for patients with chronic hepatitis D to stop taking the drug bulevirtide. Researchers will stop treatment in 20 patients whose virus is well-controlled and monitor them for a year to see who stays healthy and who relapses. The goal is to personalize treatment, potentially reducing long-term medication use and the risk of dangerous viral flare-ups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS D, CHRONIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Charité - University Hospital Berlin (Campus Virchow-Clinic); Department of Hepatology and Gastroenterology
Berlin, State of Berlin, 13353, Germany
-
Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico; Division of Gastroenterology and Hepatology
Milan, 20122, Italy
-
Hannover Medical School; Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology
Hanover, Lower Saxony, 30625, Germany
-
University Hospital Frankfurt; Medical Clinic 1
Frankfurt am Main, Hesse, 60590, Germany
-
University Hospital Heidelberg; Department of Internal Medicine IV: Gastroenterology, Hepatology, Infectious Diseases, Poisoning
Heidelberg, Baden-Wurttemberg, 69120, Germany
Conditions
Explore the condition pages connected to this study.